Archetype Partners
The interesting question isn't how AI fits into your business.
Most healthcare AI work right now is optimization in disguise. Faster planning, faster pilots, faster review cycles, same operating model underneath. The next version of the business is a redesign, not a retrofit: built around AI in the workflows, the governance, and the way business decisions actually get made.
Impact partner
We work with you to articulate the strategy, drive the alignment, define the workflows and requirements, and build the working system. Pilots won't decide healthcare's next chapter. That redesign starts in the operating model, not at the technology layer.
In healthcare, growth doesn't come from shipping faster. It comes from how decisions move across regulated review, how field and clinical teams adapt, and how evidence becomes commercial action. At a pharma, that crosses the medical-commercial firewall. At a payer, it crosses utilization management. At a provider system, it crosses care-pathway review. AI changes those mechanics. It isn't a faster version of the old playbook.
Most regulated AI programs don't fail at the technology. They stall at clinical review, privacy review, the pharmacist or field workflow, the actuarial sign-off, the LMR/PRC cycle, or the pilot-to-production handoff. Designing for those gaps is the work.
The companies that get this right will rebuild Medical Affairs, commercial, network strategy, clinical operations, and digital around AI as foundation, not as another tool to roll out.
They're optimizing slide decks, billing models, and partner pyramids around AI instead of redesigning themselves. Archetype was built AI-native from day one. No legacy structure to defend.
Services
From operating-model redesign through executive recruiting. Strategy, requirements, prototype, and pilot inside the same engagement.
Insights
Long-form thinking on AI-native growth in regulated markets.
Your pilots work. Something in the cost base moved. And every use case that tries to become the way the company actually operates stalls in the same place - on a decision right, a headcount, a review gate, or a definition of done. That limit has a name.
Most established pharma orgs stall at the ownership question before they ever get to the work.
FAQ
Archetype is a strategy and implementation firm for AI-native business design in regulated industries. The work begins upstream of the pilot list and ends in an AI-native business function, with the operating-model redesign in between. Built for pharma, biotech, payers, providers, pharmacies, medical devices, and health-tech.
Established healthcare incumbents and growth-stage health-tech past Series B, where the commercial model is real and the regulated context is real. Pharma. Biotech. Payers. Provider systems. Pharmacies. Medical devices. Buyers are typically the CCO, CDO, Chief AI Officer, Head of Commercial Strategy, Head of Network or Clinical Strategy, or Head of Medical, often within the first six months of an AI mandate from the board.
Generic AI strategy hands you a recommendation that stops at the regulated questions. Privacy review, clinical workflow, claims substantiation, the field workflow, utilization-management review at a payer, pharmacist review at a pharmacy, MLR throughput at a pharma: all treated as out of scope. The operating model never gets touched. Archetype starts where the recommendation stops, and treats the regulated context as a foundational design input, not a constraint to apologize for.
Most engagements run six to sixteen weeks and produce one of three things: an AI-native operating-model redesign, a strategy-to-prototype sprint inside a specific function (commercial, medical, clinical, network, or field), or an executive advisory engagement when the question is board-level and time-sensitive. About half the time, an engagement that started as one of those becomes one of the others.